Companies & Industry »Company News
Divis Laboratories Ltd - Company News

BSE   14 Jun 19 | 12:00 AM

1526.90 -19.1 (-1.24%)
Mkt Price (Rs)   Chg Rs (Chg %)
Code: 532488
Face Value: 2

NSE   14 Jun 19 | 12:00 AM

1522.30 -24.25 (-1.57%)
Mkt Price (Rs)   Chg Rs (Chg %)
Code: DIVISLAB
Performance
1 Week : Rs 1,564.40 (-2.40%)
1 Month : Rs 1,642.50 (-7.04%)
1 Year : Rs 1,084.30 (40.82%)
change companytradenow

  • 24 Apr 17
    09:23 AM
    Divi’s Laboratories hit 52-week low of Rs 607, down 4% on BSE in early morning trade after the company on Saturday said that the US drug regulator has issued a warning letter for its unit-II at Visakhapatnam, Andhra Pradesh.
  • 16 Aug 16
    10:20 AM
    Divis Laboratories has rallied 5.5% to Rs 1,255, also its record high on the BSE, after the company reported 23% year on year jump in standalone net profit at Rs 302 crore for the quarter ended June 30, 2016 (Q1FY17), on the back of strong revenue growth.
  • 19 Sep 15
    12:35 AM
    Divi’s Laboratories has gained at least 14 per cent since the end of July, outperforming the Sensex, which has not only been volatile but is also down 6.4 per cent.
  • 05 Feb 14
    12:48 AM
    The Divi's Laboratories stock on Tuesday spurted five per cent intraday on the back of a good December quarter show which saw the company beat expectations across all parameters. The stock closed with gains of 2.3 per cent at the end of trading.
  • 04 Feb 14
    12:49 PM
    Divi's Laboratories gained 3.73% to 1,362 after its net profit increased by 51.84% to Rs 219.02 crore, largely due to a 25.24% increase in total income in Q3 December 2013 over Q3 December 2012 to Rs 697.18 crore.
    12:20 AM
    Pharmaceutical company, Divi's Laboratories, posted a 52 per cent rise in net profit at Rs 219.02 crore for the third quarter ended December 31, 2013, as against Rs 144.24 crore during the corresponding period last year.
  • 09 Aug 13
    02:46 AM
    The Divi's Laboratories stock rose three per cent on Monday on the back of better-than-expected profits in the June quarter and hopes that prospects would improve from the second half of FY14. The Ebitda margins for the quarter at 38 per cent, though down
  • 06 Aug 13
    01:56 PM
    The company’s Ebidta margins for the quarter at 38% though down 130 basis points year-on-year were above analyst expectations on the back of better gross margins brought on by a superior product mix as well as lower employee and other expenses.
1|2|Next
Widgets Magazine

Sensex

Company Price Gain (%)
Larsen & Toubro1,529.150.80
Vedanta169.600.74
Sun Pharma.Inds.392.350.58
Power Grid Corpn194.600.44
TCS2,252.300.09
Widgets Magazine

Online Portfolio

You can create Online Portfolio here using the below button.

Widgets Magazine